If you are on a GLP-1 like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), you have probably heard that these drugs "cause muscle loss." It is one of the most talked about side effects right now, and for good reason. What's the point of losing weight if it ends up being muscle?
Here is the short version. Some of the weight you lose on a GLP-1 will not be fat. That part is real. But the true muscle loss is smaller than the scary headlines suggest, it is about what you would expect from any large weight loss, and fortunately, you have a lot of control over it.
As a physician who has spent about 20 years obsessed with body composition, I want to walk you through what the best research actually shows, why it matters, and what you can do to keep your muscle while the fat comes off.
How much of the weight you lose is muscle?
In the big trials, about 15% to 40% of the weight people lost on GLP-1s was "lean mass" (1-3). That sounds alarming until you understand what lean mass means.
Lean mass (also called fat-free mass) is everything in your body that is not fat. That includes muscle, but also water, bone, your liver, and your other organs. Muscle makes up only about half of it. So "lean mass" and "muscle" are not the same thing (4-5).
Here is what the major studies found:
| Study | Drug | What they found |
|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | Of 13.6 kg (about 30 lb) lost, 5.3 kg (38%) was lean mass. That works out to roughly 20% of the weight loss being actual muscle (4-5). |
| SURMOUNT-1 | Tirzepatide 15 mg | Over 72 weeks, fat mass dropped 33.9% and lean mass dropped 10.9%. About 25% of the weight lost was fat-free mass (2, 5). |
| Meta-analyses (many trials combined) | Several GLP-1s | Lean loss made up about 15% to 25% of total weight loss. A review of 22 randomized trials put it at about one quarter (3, 6, 16). |
Two details from these studies get left out of most headlines. First, in STEP 1 the ratio of lean mass to total body mass actually went up. In other words, people ended up with a better body composition, not a worse one (4-5). Second, in a tirzepatide study using MRI, thigh muscle shrank in proportion to the weight lost, but the amount of fat stored inside the muscle also went down (6). Less fat inside muscle generally means healthier muscle.
There is also a measurement problem. The common tools used to measure body composition, DXA scans and bioelectrical impedance (BIA), count water, liver, and other organs as lean mass. When you lose weight, your liver often shrinks too, especially if it was fatty. That shows up as "lean mass loss" even though it is a good thing. So these numbers likely overstate true muscle loss (2, 6).
The overall quality of this evidence is also mixed. One meta-analysis rated its findings as low certainty, with results varying a lot from study to study (3).
Why muscle loss matters
Muscle is not just about looking good. It is one of the most important organs you have for long-term health. Losing too much of it during weight loss could work against the very goals you started the medication for (5, 7).
Strength and independence. Muscle lets you climb stairs, carry groceries, and get up off the floor. Losing too much can raise the risk of falls and make daily life harder, especially as you get older. In observational studies of older adults with type 2 diabetes on semaglutide, grip strength, walking speed, and muscle mass declined. Those studies cannot prove the drug caused it, but they are worth paying attention to (5-6, 12-13).
Blood sugar control. Muscle is where most of the sugar in your blood goes after a meal. Less muscle could blunt some of the metabolic benefit you get from losing weight (14).
Metabolism and weight regain. Muscle accounts for about 20% to 30% of the calories you burn at rest. One theory is that losing muscle lowers your metabolism and makes you more likely to regain weight once you stop the drug. And the weight that comes back is mostly fat. Repeat that cycle a few times, and you can end up with less muscle and more fat than when you started. This idea makes sense, but it has not been proven (1, 14).
Fitness. Your cardiorespiratory fitness (how well your heart and lungs handle exercise) is one of the strongest predictors of how long you will live. Despite large amounts of weight loss, GLP-1 trials have not shown improvements in fitness (15).
Bones. Large and fast weight loss (14% or more of body weight) is linked to meaningful bone loss. Weaker bones plus weaker muscles is a bad combination for fracture risk (4).
Here is the honest part: most of this harm is still theoretical. No GLP-1 trial has measured hard, objective outcomes like falls or physical performance, and most trials show that people feel their physical function stays the same or gets better (5, 11-12).
Keeping it in perspective
GLP-1s are not uniquely bad for muscle. When you lose a lot of weight by any method, some of it will be lean mass. The muscle loss seen on these drugs is roughly what you would expect for a person's age and the amount of weight they lose. It is similar to what happens after bariatric surgery or very low calorie diets (4, 11, 13).
A 2026 systematic review in the Annals of Internal Medicine looked at this directly. Muscle-related losses were higher than expected benchmarks in about two thirds of GLP-1 type trials. But they were also higher than expected in nearly half of weight loss studies that used no drugs at all (11). The issue is big, fast weight loss, not something special about the medication. Lab studies actually suggest GLP-1 signaling is neutral or even helpful for building muscle (3, 6).
There is also a reasonable argument that some muscle loss is normal. If you drop 15% of your body weight, your legs and back have less weight to carry every day, so your body does not need quite as much muscle to move you around (12). And as mentioned above, muscle quality may improve as fat inside the muscle goes down (2, 13).
So who should actually worry? The stakes are highest for people who are:
Older, frail, or already low in muscle
Sedentary (not exercising, especially no strength training)
Likely to stop the drug and regain weight
For younger, active people who eat enough protein, the concern is mostly theoretical (6).
Why people lose muscle on GLP-1s
The muscle loss is mostly driven by how much weight comes off, how fast it comes off, and what you are (or are not) doing while it happens. The main drivers:
A big, fast calorie deficit. These drugs produce more weight loss, more quickly, than dieting alone. The more and faster you lose, the more lean mass tends to go with it (1, 4).
Not eating enough protein. The drugs cut your appetite and make you full fast. Many people also start to dislike protein-heavy foods like meat. Protein intake drops, and muscle pays the price (4, 7).
No reason for your body to keep the muscle. Muscle is expensive for your body to maintain. If you are not lifting weights, your body has little reason to hold onto it. Fatigue and stomach side effects while the dose is being increased can make people even less active (4, 8).
Personal risk factors. Older age, menopause, low testosterone, inactivity, insulin resistance, and low vitamin D all raise the risk. In one liraglutide study, 18% of people lost 10% or more of their lean mass. Men may also lose a larger share of their weight as muscle than women, about 20% to 25% versus 10% to 15% (4-5).
Regain is mostly fat. If you stop the drug and the weight comes back, it comes back mostly as fat. Cycling on and off can slowly shift your body toward more fat and less muscle (1). If you plan to come off your medication, the GLP-1 maintenance planner can help you keep your results.
How to protect your muscle on a GLP-1
The good news is that the fixes are simple, and they work. If you only do one thing on this list, make it strength training.
1. Lift weights (this matters most)
Resistance training has the strongest evidence of anything here. In weight loss studies using diet alone, strength training cut lean mass loss by 50% to 95% (4, 9).
A joint advisory from four major nutrition and obesity organizations recommends (4):
Strength training at least 3 times per week
At least 150 minutes per week of moderate cardio, like brisk walking
Starting slowly and building up over time
Other experts suggest 2 to 3 strength sessions per week, totaling 60 to 90 minutes, as a realistic target (9). Cardio alone does a worse job of protecting muscle. And in one randomized trial, people who combined a GLP-1 with exercise kept their bone density, while those on the drug alone lost some (4, 9).
You do not need to live in the gym. Two or three full body sessions a week, done consistently, will get you most of the benefit.
2. Eat enough protein
There are no studies yet that set a protein target specifically for GLP-1 users. Experts have borrowed targets from bariatric surgery: about 0.8 to 1.6 grams per kilogram of body weight per day (roughly 0.35 to 0.75 grams per pound), or about 80 to 120 grams per day (4, 7). For a personal starting point, try the GLP-1 muscle preservation calculator.
When your appetite is low, getting there takes a plan:
Eat your protein first at every meal, before you fill up
Pick protein-dense foods that do not take up much room, like Greek yogurt, eggs, fish, and cottage cheese
Use a protein shake if you cannot get enough from food
One important point: protein alone will not save your muscle if you are not training. And eating far more than you need does not build extra muscle (4, 7).
3. Track strength, not just the scale
How strong you are and how well you move tells you more than a lean mass number on a scan (6). Useful things to check before you start and as you go (4, 8-9):
Grip strength, how many times you can stand up from a chair, and how fast you walk
Whether your lifts in the gym are holding steady or going up
Body composition: a BIA scale is practical for tracking trends, and a DXA scan every 1 to 2 years is an option
This is especially important if you are older, frail, or already low in muscle.
4. Supplements (weaker evidence)
Creatine, leucine or BCAAs, omega-3s, and vitamin D may help if the basics above are not enough. The evidence for these is much weaker than for training and protein (10). Newer drugs designed to protect muscle, such as bimagrumab, are still experimental (10).
The bottom line
Yes, you will lose some lean mass on a GLP-1. But a good chunk of that is water and organ tissue, not muscle, and the muscle loss you do see is about the same as with any large weight loss. The drug is not attacking your muscle. Big, fast weight loss without enough protein or strength training is the real problem.
That means it is largely in your hands. Lift weights two to three times a week, hit your protein target, and track your strength along the way. Do that, and a GLP-1 can help you lose fat while keeping the muscle that keeps you strong, healthy, and independent for decades.
If you want help building a plan to protect your muscle while you lose fat, book a free 30-minute intro session with me at Arete Health.
This article is for education only and is not medical advice. Talk with your own doctor before starting, stopping, or changing any medication.
References
Lieberman DE, Aslan DH, Heymsfield SB. The conundrum of exercise for weight management in the GLP-1 receptor agonist era. JAMA. 2026.
Jalleh RJ, Talley NJ, Horowitz M, Nauck MA. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. J Clin Invest. 2026.
Beaudart C, Malréchauffé Y, van Heden S, et al. GLP-1 receptor agonists and musculoskeletal outcomes: a systematic literature review and meta-analysis. Drugs. 2026.
Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Am J Clin Nutr. 2025.
Kunutsor SK, Seidu S. Safety and tolerability of glucagon-like peptide-1 receptor agonists: a state-of-the-art narrative review. Drugs. 2026.
Zhang J, Zhai X, Sha S, Zhang L. Glucose-lowering therapies in type 2 diabetes-associated sarcopenia: mechanisms, clinical evidence and a muscle-centred framework. Drugs. 2026.
Spreckley M, Ruggiero CF, Brown A. Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: lessons from bariatric surgery. Int J Obes. 2026.
Sukurica E, Sengul GF, Uysal Cinar F. Weight loss or muscle loss? Cellular mechanisms and clinical strategies for preserving lean mass during GLP-1-based therapy. Diabetes Obes Metab. 2026.
Mehrtash F, Dushay J, Manson JE. Integrating diet and physical activity when prescribing GLP-1s: lifestyle factors remain crucial. JAMA Intern Med. 2025.
Chavez AM, Carrasco Barria R, León-Sanz M. Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary? Curr Opin Clin Nutr Metab Care. 2025.
Batsis JA, Gavras A, Gross DC, et al. Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review. Ann Intern Med. 2026.
Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026.
Gonzalez-Rellan MJ, Drucker DJ. New molecules and indications for GLP-1 medicines. JAMA. 2025.
Zitzmann M, Bosnyak Z, Jones R, Caliber M. Weight regain after incretin treatment: the lean mass deficit hypothesis and a role for testosterone combination therapy in men. Diabetes Obes Metab. 2026.
Liu Z, Weeldreyer NR, Angadi SS. Incretin receptor agonism, fat-free mass, and cardiorespiratory fitness: a narrative review. J Clin Endocrinol Metab. 2025.
Jobanputra R, Sargeant JA, Plekhanova T, et al. The effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on lean body mass in humans: a systematic review and meta-analysis of randomised controlled trials. Diabetes Metab Res Rev. 2026.
